Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Furoscix, SPN-830 Show Difficulties Of Drug-Device Combinations

Oct 14 2022

• By Bridget Silverman

Keeping Track Feature image

Related Content

US FDA Continues Shutout Of Companies Seeking Drug Rejection Hearings

Sep 14 2022

Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL

Dec 12 2020

Keeping Track Of US FDA Decisions: Approvals For Ongentys And New Keytruda, Darzalex Dosing, But Not For Trevyent

May 04 2020

Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label

Dec 11 2021

Repatha Monthly Dose Approved With On-Body Pushtronex System

Jul 11 2016

ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission

Jul 14 2021

Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT

Jun 15 2018

Related Companies

Supernus Pharmaceuticals, Inc.

scPharmaceuticals, Inc.

West Pharmaceutical Services, Inc.

Amgen, Inc.

Britannia Pharmaceuticals Ltd

US WorldMeds, LLC

United Therapeutics Corporation

SteadyMed Ltd.

Intarcia Therapeutics, Inc.

Zosano Pharma Corporation

Additional Topics

United States Complete Response Letters Approvals Drug Review Drug Approval Standards Regulation US FDA Performance Tracker Combination Products Cardiovascular Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window